Cargando…

FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma

BACKGROUND: Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet well studied and there are no effective therapies for these patients. METHODS: For...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yue, Shi, Tao, Wang, Xuan, Hu, Jinwei, Yu, Lixia, Liu, Qin, Wu, Nandie, Liu, Baorui, Wei, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459493/ https://www.ncbi.nlm.nih.gov/pubmed/34551773 http://dx.doi.org/10.1186/s12967-021-03079-8

Ejemplares similares

Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer
por: Wu, Nandie, et al.
Publicado: (2023)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Prognostic significance of poorly cohesive gastric carcinoma in Tunisian patients
por: Jouini, Raja, et al.
Publicado: (2020)

Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population‐based study
por: Shi, Tao, et al.
Publicado: (2019)

Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management
por: Drubay, Vincent, et al.
Publicado: (2022)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020)

YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer
por: Bencivenga, Maria, et al.
Publicado: (2023)

Comparison of Gene Expression Profiles of Signet Ring Cell Carcinoma and Poorly Cohesive Carcinoma in Early Gastric Cancer
por: Yeo, Min Kyung, et al.
Publicado: (2022)

FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
por: Tao, Zhanchao, et al.
Publicado: (2022)

CircARVCF Contributes to Cisplatin Resistance in Gastric Cancer by Altering miR-1205 and FGFR1
por: Zhang, Ruirui, et al.
Publicado: (2021)

TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma
por: Yue, Guofeng, et al.
Publicado: (2014)

Individualised adjuvant immunotherapy with neoantigen‐reactive T cells for gastric signet‐ring cell carcinoma
por: Ding, Naiqing, et al.
Publicado: (2023)

Synergistic Anticancer Effects of Polyphyllin I and Evodiamine on Freshly-Removed Human Gastric Tumors
por: Yue, Guofeng, et al.
Publicado: (2013)

FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention
por: Wang, Yijun, et al.
Publicado: (2021)

Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation
por: He, Qin, et al.
Publicado: (2021)

Establishment of cohesion 1 homolog 2 facilitates cell aggressive behaviors and induces poor prognosis in renal cell carcinoma
por: Wang, Qiu‐Li, et al.
Publicado: (2020)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

The efficacy of treating patients with non-metastatic gastric linitis plastica using surgery with chemotherapy and/or radiotherapy
por: Song, Xueru, et al.
Publicado: (2020)

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
por: Jogo, Tomoko, et al.
Publicado: (2021)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Poorly cohesive adenocarcinoma of the ampulla of Vater: a case report
por: Yamauchi, Hayato, et al.
Publicado: (2016)

Ultrastructural Evidence of Eosinophil Clustering and ETosis in Association with Damage to Single Tumour Cells in a Case of Poorly Cohesive NOS Gastric Carcinoma
por: Caruso, Rosario, et al.
Publicado: (2023)

Cohesive and Non-Cohesive Gold
por: Rice, J. S.
Publicado: (1875)

FGFR families: biological functions and therapeutic interventions in tumors
por: Liu, Qing, et al.
Publicado: (2023)

Molecular Landscape and Association With Crohn Disease of Poorly Cohesive Carcinomas of the Nonampullary Small Bowel
por: Tedaldi, Gianluca, et al.
Publicado: (2023)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
por: Pu, Xiaohong, et al.
Publicado: (2023)

In situ gelatinase-responsive and thermosensitive nanocomplex for local therapy of gastric cancer with peritoneal metastasis
por: Wang, Xinyue, et al.
Publicado: (2022)

Cohesive and Non Cohesive Golds—Correspondence
Publicado: (1881)

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2013)

Oil exposure alters social group cohesion in fish
por: Armstrong, Tiffany, et al.
Publicado: (2019)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

Characterization of Poorly Cohesive and Signet Ring Cell Carcinomas and Identification of PTPRM as a Diagnostic Marker
por: Bae, Go Eun, et al.
Publicado: (2022)

Force Transmission Modes of Non-Cohesive and Cohesive Materials at the Critical State
por: Wang, Ji-Peng
Publicado: (2017)

Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer
por: Lee, Jonghoon, et al.
Publicado: (2022)

The Relative Values of Non Cohesive and Cohesive Gold
por: Curtis, I. C.
Publicado: (1892)

Combination of Cohesive and Non-Cohesive Gold in Filling
por: Johnson, C. N.
Publicado: (1894)

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
por: Benjamin, David J., et al.
Publicado: (2023)

A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer
por: Shen, Jie, et al.
Publicado: (2013)

Correction: ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_idd02f5mhdlcgjdv5e94fdgkkd